Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02346435 · ClinicalTrials.gov registry record
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
A clinical trial of Kidney Neoplasm, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT02346435 is a study of Kidney Neoplasm that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 600 participants, above the 67-participant average among 4 other Kidney Neoplasm trials with a reported enrollment target (796% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02346435, a study of Kidney Neoplasm, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \<=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.
Conditions Studied
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2009-01 |
| Est. Completion | 2028-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02346435
The ClinicalTrials.gov registry entry for NCT02346435 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 4 other Kidney Neoplasm trials with a reported enrollment target (796% higher). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Neoplasm appearing as the primary indexed condition, and to 0 interventions.
NCT02346435 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02346435 about?
NCT02346435 is a clinical study titled "The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry". Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \<=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.
What is the current status of trial NCT02346435?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2009-01. Estimated completion is 2028-01.
What conditions does trial NCT02346435 study?
This clinical trial studies the following conditions: Kidney Neoplasm.
Who is sponsoring clinical trial NCT02346435?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02346435 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
SPECT/CT for the Characterization of Renal Masses
ACTIVE NOT RECRUITING
-
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
ACTIVE NOT RECRUITING · Phase 2
-
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.